Lih-Wen Mau
Overview
Explore the profile of Lih-Wen Mau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1076
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bhatt N, Meyer C, Mau L, Auletta J, Baker K, Broglie L, et al.
Bone Marrow Transplant
. 2024 Feb;
59(5):653-659.
PMID: 38378916
To understand transplant center recommendations on return-to-school timing and related support for hematopoietic cell transplant (HCT) survivors, we conducted a two-phase, cross-sectional, web-based survey: In Phase I, medical directors of...
2.
Barata A, Abrams H, Meyer C, Mau L, Mattila D, Burns L, et al.
Blood Adv
. 2023 Mar;
7(10):2032-2041.
PMID: 36877661
Palliative care (PC) benefits patients undergoing hematopoietic stem cell transplantation (HSCT), but it remains underutilized. Although transplant physicians report concerns regarding how patients perceive PC, HSCT recipients' perceptions about PC...
3.
Dhakal B, Zhang M, Burns L, Tang X, Meyer C, Mau L, et al.
Haematologica
. 2023 Jan;
108(8):2249-2254.
PMID: 36601982
No abstract available.
4.
Preussler J, Meyer C, Coles J, Yoo D, Mau L, Garrett N, et al.
JCO Clin Cancer Inform
. 2022 Oct;
6:e2200069.
PMID: 36228178
Purpose: Administrative claims data provide real-world service utilization of acute myeloid leukemia (AML) treatment, but lacks insight into treatment delays or barriers. The National Marrow Donor Program (NMDP)/Be The Match...
5.
Mau L, Preussler J, Meyer C, Senneka M, Wallerstedt S, Steinert P, et al.
Transplant Cell Ther
. 2022 Sep;
28(12):852-858.
PMID: 36170959
Allogeneic hematopoietic cell transplantation (alloHCT) is a resource-intensive procedure and the sole potentially curative treatment available for patients with acute myelogenous leukemia (AML). Although Medicare coverage may help address a...
6.
Cusatis R, Flynn K, Vasu S, Pidala J, Muffly L, Uberti J, et al.
Transplant Cell Ther
. 2021 Nov;
28(2):112.e1-112.e9.
PMID: 34757219
The importance of patient-reported outcomes (PROs) in cellular therapies, including hematopoietic cell transplantation (HCT) is highlighted in this study. Longitudinal collection of PROs in a registry is recommended for several...
7.
Bhatt N, Meyer C, Mau L, Broglie L, Devine S, Choi S, et al.
Transplant Cell Ther
. 2021 Sep;
28(1):54.e1-54.e4.
PMID: 34543770
Although organizations such as Centers for Disease Control and Prevention and American Academy of Pediatrics have published guidelines favoring the resumption of in-person schooling during the coronavirus disease 19 (COVID-19)...
8.
Mock J, Meyer C, Mau L, Nguyen C, Arora P, Heron C, et al.
Transplant Cell Ther
. 2021 Jul;
27(10):869.e1-869.e9.
PMID: 34224915
Allogeneic hematopoietic cell transplantation (HCT) is a standard therapy for patients with intermediate to high-risk acute myeloid leukemia (AML) and is associated with improved long-term disease-free survival. Disparity exists in...
9.
Mupfudze T, Meyer C, Preussler J, Mau L, Bolon Y, Steinert P, et al.
Transplant Cell Ther
. 2021 Apr;
27(8):685.e1-685.e8.
PMID: 33895405
Compared with privately insured patients, recipients of Medicaid have been reported to have worse outcomes in several clinical conditions and following various surgical and medical procedures. However, the relationship between...
10.
Bhatt N, Brazauskas R, Salit R, Syrjala K, Bo-Subait S, Tecca H, et al.
Transplant Cell Ther
. 2021 Apr;
27(8):679.e1-679.e8.
PMID: 33895402
Young adult (YA) survivors of allogeneic hematopoietic cell transplantation (HCT) are at risk for late psychosocial challenges, including the inability to return to work post-HCT. Work-related outcomes in this population...